Abstract
Early in the pandemic, concerns were raised about the potential for serious and widespread neurological and psychiatric adverse outcomes following COVID-19, on the basis of a systematic review of observational studies done in patients infected during previous coronavirus epidemics.1 Interpretation was hampered by the absence of a comparison group of individuals who had similar infections. The first large-scale attempt to redress this issue was published by Maxime Taquet and colleagues2 who found, using real-world data, that a first psychiatric diagnosis was more common in patients with COVID-19 in the 14–90 days after SARS-CoV-2 infection than in those with several other acute illnesses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
